Current partner codePEPTIDESDE
NCT06255366·Phase 4·INTERVENTIONAL

Analysis of the Clinical Efficacy of Intravenous Application of Hemostatic Drugs in Improving the Clarity of Vision Under Endoscope, Perioperative Bleeding Volume and Anti-inflammatory Effect of Spinal Endoscopic Lumbar Fusion

Status

Unknown

Phase

Phase 4

Enrollment

126

Locations

0

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

To study the clinical efficacy of carosodiumsulfonate and desmopressin in improving the clarity of vision under endoscope, perioperative bleeding volume and anti-inflammatory effect in endoscopic lumbar fusion

Full detailed description

A total of 129 patients diagnosed with lumbar spondylolisthesis and undergoing endoscopic lumbar fusion in our hospital from February 2024 to February 2025 were prospectively enrolled in this trial. All subjects who met the inclusion criteria were enrolled in the trial after signing the informed consent form. After completing the relevant information registration, routine preoperative preparation was performed and relevant baseline data were collected. The randomization scheme was completed by specialized statisticians independently and was not affected by the subjective will of the researchers and the subjects. According to the random number table method, all subjects were equally allocated to group A, group B and group C at a ratio of 1:1:1. Participants and investigators were blinded to group assignments until the end of the study and were blinded only if a participant developed a serious complication during treatment. Blood routine, liver function, renal function, electrolytes, coagulation indexes and other hematological tests were routinely performed before operation. The volume of blood drawn was about 15ml. Experimental group (group A) : Intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (caroxime sodium sulfonate 80mg and sodium chloride 0.9g) (Chongqing Dikang) was given 5 minutes before operation. One hour after operation, intravenous infusion of carosene sodium sulfonate injection 100ml (carosene sodium sulfonate 80mg and sodium chloride 0.9g) (Chongqing Dicang) \[reference to Weiluojing (Carosene sodium sulfonate sodium chloride injection) 100ml (80mg: 0.9g) Usage and dosage: intravenous infusion of 80mg each time (approval number: Chinese Medicine approval number H20052472)\]; Experimental group (group B) : Intravenous infusion of desmopressin injection 15ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml 5 minutes before surgery, intravenous infusion of desmopressin injection 15ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml 1 hour after surgery \[according to the instructions of desmopressin injection (Hangu), usage and dosage: 1. Control of bleeding or prevention of bleeding before operation: according to the dose of 0.3ug/kg body weight, diluted to 50-100ml with normal saline, intravenous infusion within 15-30min (approval number: H20064093); In control group (group C), 100ml 0.9% sodium chloride solution was intravenously infused 5 minutes before surgery and again 1 hour after surgery. Intraoperative Gertzbein-Sload (GS) score was used to score the clarity of the intraoperative visual field under the microscope. During the operation, the operation time and the total amount of perfusate were recorded, and the red blood cell count was measured by taking the perfusate from the drainage bottle. The blood routine, erythrocyte sedimentation rate, CRP and IL-6 were rechecked at 3 days, and the amount of blood drawn was about 10ml each time. The total blood loss, intraoperative blood loss and hidden blood loss of the patients were recorded, and the VAS scores at 1 day, 2 days and 3 days after operation were recorded. To evaluate the effect of intravenous administration of carosodiumsulfonate and desmopressin on the clarity of visual field under endoscope, perioperative blood loss and postoperative inflammatory indicators in endoscopic lumbar fusion.

Interventions

Treatment arms and agents.

DRUG

Caroxime sodium sulfonate

Five minutes before surgery, intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) (trade name: Weiluojing, 100ml, containing caroxime sodium sulfonate 80mg and sodium chloride 0.9g, Chongqing Dikang Changjiang Pharmaceutical Co., LTD.) was given, and intravenous infusion of caroxime sodium sulfonate and sodium chloride injection 100ml (80mg) was given again 1 hour after surgery.

DRUG

Desmopressin

Intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given 5 minutes before surgery, and intravenous infusion of desmopressin injection 4ug (Shenzhen Hanyu) +0.9% sodium chloride injection 100ml was given again 1 hour after surgery

DRUG

0.9% Sodium Chloride Injection

Intravenous infusion of 0.9% sodium chloride injection 100ml (specification 100ml, containing 0.9g sodium chloride, Sichuan Kelun Pharmaceutical Co., LTD.) was given 5 minutes before surgery, and intravenous infusion of 0.9% sodium chloride injection 100ml was given again 1 hour after surgery

Timeline

From registration to results.

  1. First posted

    Feb 13, 2024

  2. Study start

    Mar 28, 2024

  3. Primary completion

    Dec 30, 2024

  4. Study completion

    Jun 29, 2025

  5. Results posted

    Not reported

  6. Registry updated

    Mar 15, 2024

Outcomes

What the study measures.

Primary outcomes

Clarity under microscope

Time frame · During the operation

Grade 1: Vital areas cannot be seen clearly but is sufficient to perform surgery. Means that the visual field quality of the operation is low, but sufficient for simple surgical procedures. Grade 2: Visual field clarity is good enough to perform fast and accurate surgery. It means that the quality of the surgical field is good and the operation can be performed efficiently. Grade 3: Excellent visual acuity, can perform difficult surgery. It means that the surgical field is very clear and can perform difficult operations.

Total Blood Loss(TBL)

Time frame · During the operation

Preoperative blood volume was calculated according to the Nadler equation, preoperative blood volume (PBV)=K1× height (m)3+ K2× body weight (kg) + K3(male: K1=0.366 9, K2=0.032 19, K3=0.604 1; Female: K1=0.356 1, K2=0.033 08, K3=0.183 3). The Delphi formula was used to calculate the total blood loss of patients, total blood loss = preoperative blood volume ×2× (preoperative hematocrit - postoperative hematocrit)/(preoperative hematocrit + postoperative hematocrit)

Intraoperative Blood Loss(IBL)

Time frame · During the operation

Intraoperative Blood Loss (IBL) : IBL = Amount of fluid collected from the drainage bottle + Weight increase of gauze used during the operation - Amount of lavage fluid used during the operation

Hidden Blood Loss(HBL)

Time frame · During the operation

Hidden Blood Loss(HBL) = Total Blood Loss(TBL) -Intraoperative Blood Loss(IBL)

Duration of surgery

Time frame · During the operation

Intraoperative perfusion fluid consumption

Time frame · During the operation

Red blood cells were counted in the postoperative drainage fluid

Time frame · Up to 72 hours after surgery

Intraoperative blood pressure values

Time frame · During the operation

Systolic and diastolic blood pressure

Secondary outcomes

Erythrocyte sedimentation Rate(ESR)

Time frame · Up to 72 hours after surgery

Visual analogue scale

Time frame · Up to 72 hours after surgery

Pain was evaluated using a visual analogue scale (VAS) where 0 was no pain and 10 was unbearable pain.

IL--6

Time frame · Up to 72 hours after surgery

Interleukin- 6

C-reactive protein

Time frame · Up to 72 hours after surgery

Eligibility

Who can take part.

Minimum age
35 Years
Maximum age
65 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: 1. Patients, aged 35-65 years old, who were diagnosed as single-segment lumbar spondylolisthesis without spondylolysis based on imaging data and underwent endoscopic lumbar interbody fusion. 2. In patients with normal platelet count, blood coagulation function. 3. No history of major lumbar trauma and previous lumbar surgery. 4. No allergy history, contraindications and serious adverse reactions to desmopressin and carosodiumsulfonate. 5. American Society of Anesthesiologists (ASA) classification: grade 1-2 6. The participants and their family members were informed of the nature of the study, understood the provisions of the study, complied well, and signed informed consent Exclusion Criteria: 1. Patients who do not consent to participate in the trial. 2. Poorly controlled hypertension with systolic blood pressure \>180 mmHg or diastolic blood pressure \>110 mmHg. 3. People with mental illness, or poor compliance of patients. 4. Patients with severe liver function impairment and creatinine clearance \<20ml/min. 5. Patients with coagulopathy or inability to tolerate surgery. 6. Patients with other lumbar spine diseases or pulmonary tuberculosis. 7. ASA anesthesia level 3 or higher. 8. Patients with a long history of smoking, alcohol abuse, or contraceptive drug abuse. 9. Patients with serious heart disease, diabetes. 10. Imaging tip is merged with other lumbar disease or accompanied by lumbar spondylolysis patients. 11. Pregnant women. 12. Patients with a history of major lumbar trauma or lumbar surgery.

Study locations

0 registered sites.

No country data reported. Showing up to 24 locations stored in the fast local snapshot.

No study locations reported.

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Desmopressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.